Servier

GeNeuro is a clinical-stage biotechnology company based in Plan-Les-Ouates, Switzerland, specializing in the development of therapeutic drugs for diseases linked to the expression of pathogenic proteins derived from human endogenous retroviruses. The company primarily targets nervous system disorders, including multiple sclerosis and schizophrenia. Its lead product, GNbAC1, is a therapeutic monoclonal antibody aimed at treating multiple sclerosis, while temelimab, another candidate, neutralizes a pathogenic protein associated with the HERV-W family. In addition to its therapeutic developments, GeNeuro also focuses on creating diagnostic tests to measure multiple sclerosis-associated retrovirus-ENV proteins in patients. Founded in 2006, GeNeuro is committed to addressing the underlying causes of neurodegenerative and autoimmune diseases.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering and developing innovative treatments for cancer and rare genetic disorders related to cellular metabolism. The company specializes in small-molecule medicines targeting metabolic pathways, particularly in the context of hematologic malignancies, solid tumors, and genetic diseases. Agios offers TIBSOVO, an oral inhibitor for relapsed or refractory acute myeloid leukemia (AML), and IDHIFA, which targets AML patients with specific genetic mutations. Both drugs are undergoing various stages of clinical trials for broader applications, including frontline AML and cholangiocarcinoma. The company is also advancing other therapeutic candidates, such as mitapivat for pyruvate kinase deficiency, vorasidenib for solid tumors, and AG-270 for specific cancer types. Agios Pharmaceuticals employs a precision medicine approach to its research, aiming to identify genetically defined patient populations to enhance the efficacy of its treatments.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAbs), a novel biopharmaceutical class. The company focuses on creating treatments and prophylactics for severe human diseases, with a particular emphasis on cancer and infectious diseases. Their pipeline includes rpAb compositions for treating idiopathic thrombocytopenic purpura, preventing hemolytic disease in newborns, and mitigating adverse reactions from smallpox vaccinations, aiming to facilitate faster cancer treatment initiation and enhance overall treatment success.